Danaher said that it expects the acquisition to be accretive to earnings in the fifth full year post acquisition.
Danaher Q2 net earnings fell 5 percent to $656.7 million, or $.94 per diluted share, from $695.7 million, or $.97 per diluted share, a year ago.
The company posted sales of $5.39 billion, up from $4.69 billion in the year-ago quarter, and beating the consensus Wall Street estimate of $5.33 billion.
Danaher's full-year revenues rose nearly 8 percent with its life sciences and diagnostics business its best-earning segment for both Q4 and FY2015.
Executives from Thermo Fisher Scientific, Qiagen, Danaher, Counsyl, Human Longevity, and Adaptive Biotechnologies provided business updates to conference goers.
The firm also reaffirmed is guidance for EPS for the fourth quarter of 2015 in advance of an investor meeting in New York.
Roche has received regulatory clearance to finalize its acquisition of Kapa Biosystems, the company announced this week.
The investment bank also raised its outlook on the life science tools sector, lowered its view of labs, and stayed steady on diagnostics.
Life Science and Diagnostics sales grew almost 15 percent year over year, helped by the purchase of Pall.
Net proceeds from the offering are expected to be $1.98 billion, which will be used to repay part of the financing that went toward Danaher's buy of Pall.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.